Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated schedule provides additional benefit to a single dose. We randomized 852 older adults (median age, 68-years) with AML/hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Freeman, Sylvie D., Thomas, Abin, Thomas, Ian, Hills, Robert K., Vyas, Paresh, Gilkes, Amanda, Metzner, Marlen, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Rachel, Almuina, Nuria Marquez, Burns, Sarah, King, Sophie, Andrew, Georgia, Gallagher, Kathleen M. E., Sellar, Rob S., Cahalin, Paul, Weber, Duruta, Dennis, Mike, Mehta, Priyanka, Knapper, Steven, Russell, Nigel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667325/
https://www.ncbi.nlm.nih.gov/pubmed/37595359
http://dx.doi.org/10.1182/blood.2023020630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667325/
https://www.ncbi.nlm.nih.gov/pubmed/37595359
http://dx.doi.org/10.1182/blood.2023020630

Ejemplares similares